Bearing in mind that triple negative breast cancer accounts for 15%–20% of breast cancers albeit being the most difficult ones to treat (Yin et al., 2020), future research will be required to develop similar phenotypic screening assays using breast cancer cell lines which express HER2, ER and/or PR. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.